183 related articles for article (PubMed ID: 11875367)
1. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms.
Mattison LK; Johnson MR; Diasio RB
Pharmacogenetics; 2002 Mar; 12(2):133-44. PubMed ID: 11875367
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
van Kuilenburg AB; De Abreu RA; van Gennip AH
Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population.
Naushad SM; Hussain T; Alrokayan SA; Kutala VK
J Gene Med; 2021 Jan; 23(1):e3289. PubMed ID: 33105068
[TBL] [Abstract][Full Text] [Related]
4. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Gross E; Ullrich T; Seck K; Mueller V; de Wit M; von Schilling C; Meindl A; Schmitt M; Kiechle M
Hum Mutat; 2003 Dec; 22(6):498. PubMed ID: 14635116
[TBL] [Abstract][Full Text] [Related]
5. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
Kleibl Z; Fidlerova J; Kleiblova P; Kormunda S; Bilek M; Bouskova K; Sevcik J; Novotny J
Neoplasma; 2009; 56(4):303-16. PubMed ID: 19473056
[TBL] [Abstract][Full Text] [Related]
6. Porcine recombinant dihydropyrimidine dehydrogenase: comparison of the spectroscopic and catalytic properties of the wild-type and C671A mutant enzymes.
Rosenbaum K; Jahnke K; Curti B; Hagen WR; Schnackerz KD; Vanoni MA
Biochemistry; 1998 Dec; 37(50):17598-609. PubMed ID: 9860876
[TBL] [Abstract][Full Text] [Related]
7. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria.
Yokota H; Fernandez-Salguero P; Furuya H; Lin K; McBride OW; Podschun B; Schnackerz KD; Gonzalez FJ
J Biol Chem; 1994 Sep; 269(37):23192-6. PubMed ID: 8083224
[TBL] [Abstract][Full Text] [Related]
8. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
Johnson MR; Wang K; Diasio RB
Clin Cancer Res; 2002 Mar; 8(3):768-74. PubMed ID: 11895907
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
Kuilenburg ABPV; Meijer J; Tanck MWT; Dobritzsch D; Zoetekouw L; Dekkers LL; Roelofsen J; Meinsma R; Wymenga M; Kulik W; Büchel B; Hennekam RCM; Largiadèr CR
Biochim Biophys Acta; 2016 Apr; 1862(4):754-762. PubMed ID: 26804652
[TBL] [Abstract][Full Text] [Related]
10. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.
Ezzeldin H; Okamoto Y; Johnson MR; Diasio RB
Anal Biochem; 2002 Jul; 306(1):63-73. PubMed ID: 12069415
[TBL] [Abstract][Full Text] [Related]
11. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W.
Vreken P; Van Kuilenburg AB; Meinsma R; van Gennip AH
Hum Genet; 1997 Dec; 101(3):333-8. PubMed ID: 9439663
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
13. Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).
Milano G
Scand J Clin Lab Invest Suppl; 2016; 245():S30-3. PubMed ID: 27454530
[TBL] [Abstract][Full Text] [Related]
14. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.
Offer SM; Fossum CC; Wegner NJ; Stuflesser AJ; Butterfield GL; Diasio RB
Cancer Res; 2014 May; 74(9):2545-54. PubMed ID: 24648345
[TBL] [Abstract][Full Text] [Related]
15. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
16. Known variant DPYD alleles do not explain DPD deficiency in cancer patients.
Collie-Duguid ES; Etienne MC; Milano G; McLeod HL
Pharmacogenetics; 2000 Apr; 10(3):217-23. PubMed ID: 10803677
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.
Hsiao HH; Yang MY; Chang JG; Liu YC; Liu TC; Chang CS; Chen TP; Lin SF
Cancer Chemother Pharmacol; 2004 May; 53(5):445-51. PubMed ID: 15132136
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase and dihydropyrimidine dehydrogenase levels are associated with response to 5-fluorouracil in Caenorhabditis elegans.
Kim S; Park DH; Shim J
Mol Cells; 2008 Oct; 26(4):344-9. PubMed ID: 18612238
[TBL] [Abstract][Full Text] [Related]
19. Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals.
Hishinuma E; Narita Y; Saito S; Maekawa M; Akai F; Nakanishi Y; Yasuda J; Nagasaki M; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
Drug Metab Dispos; 2018 Aug; 46(8):1083-1090. PubMed ID: 29769267
[TBL] [Abstract][Full Text] [Related]
20. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
